According to a recent LinkedIn post from ABM Respiratory Care, the company is supporting the Resident Boot Camp and Fellow Track Symposium at the ATS 2026 International Conference through product donations of its BiWaze Clear and BiWaze Cough devices for hands-on training. The post suggests these educational programs target incoming pediatric pulmonary fellows and participants in the FTS program, with a focus on practical skills and exposure to airway clearance technologies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights its strategy of positioning BiWaze Clear and BiWaze Cough as tools for next-generation clinicians, potentially increasing early familiarity and clinical comfort with its platform. For investors, this type of in-kind support may not have immediate revenue impact, but it could strengthen long-term adoption, brand visibility in academic and hospital settings, and ABM Respiratory Care’s competitive standing in the respiratory therapy and airway clearance market.
As shared in the post, directing readers to learn more about the BiWaze platform via an external link underscores an ongoing effort to drive interest and engagement around its product suite. If the exposure at ATS 2026 translates into broader clinical use, it could support future sales growth across multiple care settings, although the scale of any financial impact will depend on subsequent commercialization and reimbursement dynamics.